Fractional Photothermolysis versus triple therapy for the treatment of melasma: a randomised controlled trial

Fractional Photothermolysis versus triple therapy for the treatment of melasma: a randomised controlled trial - Fraxel laser in melasma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31310

Enrollment

Registered

2007-09-25

Start date

2007-10-20

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chloasma mask of pregnancy

Interventions

Triple therapy Triple therapy will be applied once daily for 8 weeks. The triple therapy combines a moderately potent corticosteroid (triamcinolon acetonide 0.1%), retinoic acid 0.05% and hydrochino

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - patiënts with moderate to severe melasma - skin photo type II-V - subjects attending the outpatient department of the Netherlands Institute for Pigment Disorders - age at least 18 years

Exclusion criteria

Exclusion criteria: - bleaching cream or local corticosteroids during the past 4 weeks - subjects with a history of keloid - subjects with a history of facial eczema - allergy to lidocaine - use of roaccutane in the past 6 month

Design outcomes

Primary

Measure	Time frame
Objective colour measurements by reflectance spectroscopy before and after therapy Clinical melasma score (MASI score) before and after therapy	—

Secondary

Measure	Time frame
Quality of life Patient's satisfaction	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)